A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

Medical teams at the Vanderbilt Transplant Center (VTC) are leading the way in utilization of hepatitis C-exposed donors for heart transplantation.

Jun. 28, 2018—T. Alp Ikizler, MD, an internationally known expert on the nutritional and metabolic aspects of kidney disease, will succeed Raymond Harris, MD, as director of the Department of Medicine’s Division of Nephrology and Hypertension in the Vanderbilt University School of Medicine effective July 1.

Jun. 28, 2018—An international coalition led by scientists at Vanderbilt University Medical Center and the QIMR Berghofer Medical Research Institute in Herston, Australia, has identified 48 candidate susceptibility genes for breast cancer risk, including 14 genes at loci (chromosome regions) not yet reported for breast cancer.

Jun. 21, 2018—Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.

Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.

Vanderbilt University has received a five-year, $2.5-million Physician Scientist Institutional Award from the Burroughs Wellcome Fund to help bolster the dwindling number of active physician-scientists in the United States.